These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients. Groetzner J; Kaczmarek I; Landwehr P; Mueller M; Daebritz S; Lamm P; Meiser B; Reichart B Eur J Cardiothorac Surg; 2004 Mar; 25(3):333-41. PubMed ID: 15019657 [TBL] [Abstract][Full Text] [Related]
6. Renal function in heart transplant patients after switch to combined mammalian target of rapamycin inhibitor and calcineurin inhibitor therapy. Helmschrott M; Rivinius R; Bruckner T; Katus HA; Doesch AO Drug Des Devel Ther; 2017; 11():1673-1680. PubMed ID: 28652705 [TBL] [Abstract][Full Text] [Related]
7. Kidney transplantation as a therapeutic option for end-stage renal disease developing after heart transplantation. Grupper A; Grupper A; Daly RC; Pereira NL; Hathcock MA; Kremers WK; Cosio FG; Edwards BS; Kushwaha SS J Heart Lung Transplant; 2017 Mar; 36(3):297-304. PubMed ID: 27642059 [TBL] [Abstract][Full Text] [Related]
8. Plasma neutrophil gelatinase-associated lipocalin and worsening renal function during everolimus therapy after heart transplantation. Imamura T; Kinugawa K; Doi K; Hatano M; Fujino T; Kinoshita O; Nawata K; Noiri E; Kyo S; Ono M Int Heart J; 2015; 56(1):73-9. PubMed ID: 25742944 [TBL] [Abstract][Full Text] [Related]
9. PRKCB is associated with calcineurin inhibitor-induced renal dysfunction in heart transplant recipients. Lachance K; Barhdadi A; Mongrain I; Normand V; Zakrzewski M; Leblanc MH; Racine N; Carrier M; Ducharme A; Turgeon J; Dubé MP; Phillips MS; White M; de Denus S Pharmacogenet Genomics; 2012 May; 22(5):336-43. PubMed ID: 22322241 [TBL] [Abstract][Full Text] [Related]
10. Prevalence of iron deficiency and anemia in pediatric heart transplant recipients. Newland DM; Spencer KL; Do LD; Knorr LR; Palmer MM; Albers EL; Friedland-Little JM; Hong BJ; Kemna MS; Hartje-Dunn C; Mark DG; Nemeth TL; Ravi-Johnson S; Law YM Clin Transplant; 2024 Jun; 38(6):e15367. PubMed ID: 38809215 [TBL] [Abstract][Full Text] [Related]
11. Emerging therapy in light-chain and acquired transthyretin-related amyloidosis: an Italian single-centre experience in heart transplantation. Di Nora C; Sponga S; Ferrara V; Patriarca F; Fanin R; Nalli C; Lechiancole A; Vendramin I; Livi U J Cardiovasc Med (Hagerstown); 2021 Apr; 22(4):261-267. PubMed ID: 33633041 [TBL] [Abstract][Full Text] [Related]
17. Changes in Renal Function After Heart Transplantation. Tsao CI; Ting M; Chou NK; Chi NH; Chen YS; Huang SC; Tsan CY; Wang CH; Yu HY; Shun CT; Wang SS Transplant Proc; 2018 Nov; 50(9):2751-2755. PubMed ID: 30401390 [TBL] [Abstract][Full Text] [Related]
18. Prognostic importance of renal function 1 year after heart transplantation for all-cause and cardiac mortality and development of allograft vasculopathy. Arora S; Andreassen A; Simonsen S; Gude E; Dahl C; Skaardal R; Hoel I; Geiran O; Gullestad L Transplantation; 2007 Jul; 84(2):149-54. PubMed ID: 17667805 [TBL] [Abstract][Full Text] [Related]
19. Benefit of early conversion from CNI-based to everolimus-based immunosuppression in heart transplantation. Gude E; Gullestad L; Arora S; Simonsen S; Hoel I; Hartmann A; Holdaas H; Fiane AE; Geiran OR; Andreassen AK J Heart Lung Transplant; 2010 Jun; 29(6):641-7. PubMed ID: 20304681 [TBL] [Abstract][Full Text] [Related]
20. Ischaemic heart disease is a risk factor for renal failure after heart transplantation. Hosková L; Viklický O; Málek I; Podzimková M; Hegarová M; Pirk J; Vítko S; Kautzner J Int J Cardiol; 2008 Jan; 123(3):358-60. PubMed ID: 17360057 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]